Pre-made Tralokinumab benchmark antibody ( Whole mAb, anti-IL13 therapeutic antibody, Anti-IL-13/P600 Antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-ab-592
Pre-Made Tralokinumab biosimilar, Whole mAb, Anti-IL13 Antibody: Anti-IL-13/P600 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Tralokinumab is a human monoclonal antibody which targets the cytokine interleukin 13, and is designed for the treatment of asthma and other inflammatory diseases. Tralokinumab was discovered by Cambridge Antibody Technology scientists, using Ribosome Display, as CAT-354 and taken through pre-clinical and early clinical development. After 2007 it has been developed by MedImmune, a member of the AstraZeneca group, where it is currently in Ph3 testing for asthma and Ph2b testing for atopic dermatitis. This makes it one of the few fully internally discovered and developed drug candidates in AstraZeneca's late stage development pipeline.
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
|Catalog No.||Package||List Price(In USD)||Discount off||Discount Price|
Size： 1mg | 10mg | 100mg
|Products Name (INN Index)||Pre-Made Tralokinumab biosimilar, Whole mAb, Anti-IL13 Antibody: Anti-IL-13/P600 therapeutic antibody|
|Highest_Clin_Trial (Jan '20)||Approved|
|100% SI Structure||5l6y:HL|
|99% SI Structure||None|
|95-98% SI Structure||None|
|Companies||Cambridge Antibody Technology;Icahn School of Medicine at Mount Sinai;LEO Pharma;MedImmune|
|Conditions Active||Atopic dermatitis;Alopecia areata|
|Conditions Discontinued||Asthma;Chronic obstructive pulmonary disease;Idiopathic pulmonary fibrosis;Ulcerative colitis|